EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel–Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan

Takeshi Nagasaka iD, Yoshiyasu Kono iD, Yosuke Kito, Takayuki Ando, Yuji Negoro, Tomoyuki Abe, Hidekazu Kuramochi, Shogen Boku iD, Tomohiko Mannami iD, Junichiro Nasu, Masafumi Inoue, Masato Nakamura und 6 weitere

Cancers · 13.07.2026 · 18 (14) · 2243

DOI: 10.3390/cancers18142243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 13.07.2026. Verfasst von Takeshi Nagasaka und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Kawasaki Medical School Hospital, Kurashiki 701-0192, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kawasaki Medical School, Department of Advanced Oncology, Kawasaki Medical School.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Platinum-based doublets are standard first-line therapy for advanced gastric cancer (GC) in the Western Pacific region, but oxaliplatin frequently induces persistent peripheral sensory neuropathy (PSN). Whether residual PSN compromises the feasibility and efficacy of subsequent paclitaxel (PTX)-based therapy remains unclear.

Methods

The IVY study was a prospective, multicenter observational trial conducted across 16 Japanese institutions. Patients with advanced GC progressing after fluoropyrimidine–platinum therapy received second-line PTX ± ramucirumab. Baseline PSN was assessed by CTCAE, PNQ, and FACT/GOG-Ntx. The primary endpoint was the incidence of grade ≥ 3 PSN during second-line therapy. Secondary endpoints included progression-free survival (PFS), overall survival (OS), time to treatment failure (TTF), tumor response, and patient-reported outcomes.

Results

Among 156 patients (90 PSN-positive, 66 PSN-negative), grade ≥ 3 PSN occurred more frequently in the PSN-positive group (16.7% vs. 4.5%; p = 0.02). Median PFS was 4.0 vs. 3.9 months (p = 0.20), and median OS was 10.3 vs. 8.1 months (p = 0.04). In multivariable analysis, residual PSN was not an independent predictor of OS (HR = 0.68 for PSN-positive vs. PSN-negative, 95% CI [0.46–1.01]; p = 0.06). Patient-reported instruments captured greater and earlier QoL impairment in PSN-positive patients, though trajectories stabilized by 12 weeks.

Conclusions

Residual PSN increases the risk of clinically relevant neurotoxicity—particularly in patients with baseline grade ≥ 2—but, in this cohort, did not appear to preclude paclitaxel-based second-line therapy when monitoring and dose modification were available. The apparent survival difference was exploratory and, after adjustment for baseline imbalance, should not be interpreted as a benefit attributable to residual PSN. Residual neuropathy should therefore prompt structured baseline assessment and early-cycle monitoring rather than routine reassurance.

Schlagwörter

Stichwörter der Autor:innen

Ramucirumabadvanced gastric canceroxaliplatinpaclitaxelperipheral sensory neuropathysecond-line chemotherapy

Autor:innen und Institutionen

  • Department of Clinical Oncology, Kawasaki Medical School Hospital, Kurashiki 701-0192, Japan.
  • Department of Advanced Oncology, Kawasaki Medical School, Kurashiki 701-0192, Japan.
  • Department of Gastroenterology and Hepatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
  • Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa 920-8530, Japan.
  • Third Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
  • Department of Oncological Medicine, Kochi Health Sciences Center, Kochi 781-8555, Japan.

ORCID-Profile: Takeshi Nagasaka, Yoshiyasu Kono, Shogen Boku, Tomohiko Mannami, Takeshi Yamada, Yudai Shinohara

Förderung

  • Kawasaki Medical School
  • Department of Advanced Oncology, Kawasaki Medical School

Zitieren

APA

Nagasaka, T., Kono, Y., Kito, Y., Ando, T., Negoro, Y., Abe, T., Kuramochi, H., Boku, S., Mannami, T., Nasu, J., Inoue, M., Nakamura, M., Okita, Y., Shindo, Y., Yamada, T., Maeda, T., Shinohara, Y., & Tanioka, H. (2026). Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel–Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan. Cancers, 18(14), 2243. https://doi.org/10.3390/cancers18142243

Vancouver

Nagasaka T, Kono Y, Kito Y, Ando T, Negoro Y, Abe T, et al. Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel–Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan. Cancers. 2026;18(14):2243. doi:10.3390/cancers18142243

BibTeX
@article{Nagasaka2026,
  author = {Nagasaka, Takeshi and Kono, Yoshiyasu and Kito, Yosuke and Ando, Takayuki and Negoro, Yuji and Abe, Tomoyuki and Kuramochi, Hidekazu and Boku, Shogen and Mannami, Tomohiko and Nasu, Junichiro and Inoue, Masafumi and Nakamura, Masato and Okita, Yoshihiro and Shindo, Yoshiaki and Yamada, Takeshi and Maeda, Tetsuya and Shinohara, Yudai and Tanioka, Hiroaki},
  title = {Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel–Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2243},
  doi = {10.3390/cancers18142243}
}
Kostenlos starten →